Board Change


C4X Discovery Holdings plc

(“C4XD”, “C4X Discovery” or the “Company”)

18 January 2024 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces that Mario Polywka, Non-Executive Director, has stepped down from the Board of Directors with immediate effect in order to focus on his recent appointment as Interim Chief Executive Officer of Evotec SE.

The Company intends to appoint a replacement Non-Executive Director and a further announcement will be made in due course.

Clive Dix, Interim Executive Chairman and Chief Executive Officer of C4X Discovery, said: “It has been a pleasure working with Mario since he joined the Board in 2021 and during this time C4X Discovery has benefitted from his deep industry insights and experience. We wish him all the best in his new role.”

C4X Discovery Holdings plc

Mo Noonan, Communications+44 (0)7876 444 977

Panmure Gordon (UK) Limited (NOMAD and Broker) +44 (0)20 7886 2500

Freddy Crossley, Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)

C4X Discovery Media – ICR Consilium

Mary-Jane Elliott, Chris Gardner, Matthew Neal +44 (0)203 709 5700

C4X Discovery (C4XD) is a pioneering Drug Discovery company, combining scientific expertise with cutting-edge technologies to efficiently deliver world‑leading medicines. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced molecular design and patient stratification capabilities, generating small molecule drug candidates across multiple disease indications focused on immuno-inflammation. We are advancing our internal portfolio which ranges from early-stage target opportunities to late-stage Drug Discovery programmes and we have two commercially partnered programmes with Sanofi and AstraZeneca, and one clinical stage candidate which has been acquired by Indivior.

For more information visit us at www.c4xdiscovery.com or follow us on twitter @C4XDiscovery.